Approved for To treat estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Vepdegestrant is a heterobifunctional protein degrader that binds to estrogen receptor (ER) and the E3 ligase cereblon (CRBN). This interaction… Side effects,…
Loading full data from Know Your Drugs Institute…